Welcome to our dedicated page for Inscorp news (Ticker: IBTN), a resource for investors and traders seeking the latest updates and insights on Inscorp stock.
InsCorp (IBTN) provides essential financial services through its community-focused banking divisions and innovative healthcare solutions. This news hub offers investors and stakeholders centralized access to official announcements and strategic developments.
Track critical updates including earnings disclosures, leadership appointments, service expansions, and regulatory filings. Our curated collection ensures timely access to material events affecting InsCorp's commercial lending operations, Medquity healthcare banking services, and Finworth digital platforms.
Key content categories include quarterly financial results, partnership announcements, technology implementations, and risk management initiatives. Each update is presented with clarity to support informed analysis of this Tennessee-based institution's market position.
Bookmark this page for streamlined monitoring of InsCorp's developments in healthcare finance and community banking. Verify critical information directly through primary sources before making financial decisions.
INSBANK (OTCQX: IBTN) reported Q4 2024 net income of $1.946 million ($0.66 per share), compared to $1.841 million in Q3 2024 and $2.267 million in Q4 2023. The bank achieved record loan growth with originations reaching $99 million in Q4 2024, up from $48 million in Q3. Year-over-year loan growth improved to 12%, with particularly strong performance in healthcare through their Medquity division.
Revenue improved 5% year-over-year to $7.0 million in Q4 2024, while net interest income increased by 5% to $6.391 million. The bank's efficiency ratio was 60.8%, with ROA at 0.88%. The Board approved a quarterly dividend increase of 10% to $0.11 per share, payable March 7, 2025, to shareholders of record February 14, 2025.
InsCorp (OTCQX: IBTN) reported Q3 2024 net income of $1,841,000 ($0.64 per share), compared to $1,820,000 ($0.63 per share) in Q2 2024 and $2,311,000 ($0.80 per share) in Q3 2023. The company saw loan growth of 4% year-over-year and 10% quarter-over-quarter, with strong performance in commercial and industrial loans. Revenue improved 6% quarter-over-quarter to $6,571,000, though declined 3% year-over-year. The Board approved a quarterly dividend of $0.10 per share, representing a 17.6% annualized increase from 2023.
InsCorp, Inc. reported net income of $1,820,000, or $0.63 per share, in Q2 2024, up from $1,763,000 in Q1 2024. The company achieved a ROAE of 10.1% and operating EPS of $0.65. Loan originations increased to $57 million in Q2, up from $23 million in Q1, with strength in Medquity, CRE, C&D, and C&I loans. The loan pipeline grew to $79 million. Medquity reported 9% Y/Y loan growth. Revenue declined 1.1% Y/Y but improved 2.7% LQA to $6,212,000. The net interest margin was 3.08%. Asset quality remains healthy with no net chargeoffs. InsCorp's Board authorized a share repurchase of 125,000 shares and declared a quarterly dividend of $0.10 per share.
InsCorp (IBTN) reported a net profit of $1,763,000 in Q1 2024, with an EPS of $0.61, down from $2,267,000 and $0.79 respectively in Q4 2023. ROA was 1.06% and ROE 9.5% in Q1 2024. Revenue declined slightly to $6,170,000, while the net interest margin decreased to 2.94% in the same period. The bank declared a quarterly cash dividend of $0.10 per share, representing a 17.6% increase from 2023.
InsCorp (OTC-PINK: IBTN) reported a strong performance in Q1 2023, achieving a net profit of